CLOPIDOGREL RESPONSE

Clopidogrel Response — CYP2C19 variants determine whether the world's most prescribed antiplatelet drug activates in your body or passes through it unchanged.

The FDA boxed warning on clopidogrel explicitly references CYP2C19 poor metabolizer status. Whole genome sequencing provides complete CYP2C19 diplotype for definitive prescribing guidance — the same information cardiologists need before stenting.

CYP2C19

About this condition

Clopidogrel (Plavix) Response

Clopidogrel (Plavix) is a thienopyridine prodrug that requires hepatic bioactivation to its active thiol metabolite by cytochrome P450 2C19 (CYP2C19). The active metabolite irreversibly inhibits the platelet P2Y12 ADP receptor, reducing platelet aggregation and preventing arterial thrombus formation. Clopidogrel is prescribed to more than 70 million patients annually worldwide — primarily for secondary prevention after acute coronary syndrome, dual antiplatelet therapy following percutaneous coronary intervention (PCI) with stent placement, prevention of recurrent stroke, and peripheral arterial disease management.

CYP2C19 metabolizer status directly determines clopidogrel's clinical effectiveness. CYP2C19 poor metabolizers (PMs) — those who carry two loss-of-function alleles, most commonly *2 (rs4244285) and *3 (rs4986893) — cannot convert clopidogrel to its active form at therapeutic rates. In landmark studies including TRITON-TIMI 38 and PLATO, CYP2C19 loss-of-function carriers had a 50-57% relative increase in major adverse cardiac events (MACE) — including stent thrombosis, myocardial infarction, and cardiovascular death — compared to extensive metabolizers. The FDA added a boxed warning to clopidogrel in 2010 explicitly recommending CYP2C19 genotyping and dose adjustment or alternative antiplatelet therapy in poor metabolizers.

CYP2C19 metabolizer phenotypes span a spectrum: ultra-rapid metabolizers (*17/*17 or *17/normal function allele) convert clopidogrel at above-normal rates and may be at elevated bleeding risk; rapid metabolizers carry one *17 allele paired with a normal function allele; extensive metabolizers (the reference standard) carry two normal function alleles; intermediate metabolizers carry one loss-of-function allele; and poor metabolizers carry two loss-of-function alleles. The CPIC guideline (Level A — highest evidence) recommends an alternative antiplatelet agent (prasugrel or ticagrelor) for CYP2C19 intermediate and poor metabolizers undergoing PCI, with particularly strong guidance for poor metabolizers in the acute coronary syndrome setting.

CYP2C19 *2 and *3 are the most common loss-of-function variants but at least 35 star alleles have been defined. Allele frequencies vary substantially by ancestry — *2 frequency ranges from ~15% in Europeans to ~30% in East Asians.

Gene locus: CYP2C19 (10q23.33)

Point-of-care CYP2C19 tests and standard pharmacogenomics panels check a fixed set of variants. Whole genome sequencing reads the complete CYP2C19 sequence — including rare functional variants and ancestry-specific alleles that fixed panels miss.

The CYP2C19 allele affecting your clopidogrel response may not be on the standard panel

Commercial pharmacogenomics panels and point-of-care cardiac genotyping tests are designed to detect the most common CYP2C19 variants — primarily *2 and *3. CPIC-defined star alleles include at least 35 variants with functional consequences, and rare loss-of-function variants (*4 through *8) and gain-of-function variants (*17 subtypes) are not interrogated by most panels. Studies have documented clinically significant CYP2C19 variants in patients who tested 'normal' on standard limited panels. Whole genome sequencing reads the complete CYP2C19 gene sequence and surrounding regulatory regions, capturing all defined star alleles including rare functional variants that fixed-content panels miss.

Your cardiologist needs an actionable diplotype before prescribing, not a variant list

The CPIC Level A guideline for clopidogrel and CYP2C19 translates genotype into a prescribing recommendation: extensive metabolizers → clopidogrel standard dosing; intermediate metabolizers → consider alternative antiplatelet; poor metabolizers → use prasugrel or ticagrelor. This diplotype-level interpretation requires knowing both alleles across the complete CYP2C19 gene. The Dante pharmacogenomics report delivers CYP2C19 diplotype and metabolizer class in a physician-ready format — the same information required to implement the FDA boxed warning and CPIC guideline at the point of prescribing.

Clopidogrel Response — CYP2C19 variants determine whether the world's most prescribed antiplatelet drug activates in your body or passes through it unchanged.

Clopidogrel (Plavix) Response

Point-of-care CYP2C19 tests and standard pharmacogenomics panels check a fixed set of variants. Whole genome sequencing reads the complete CYP2C19 sequence — including rare functional variants and ancestry-specific alleles that fixed panels miss.

The CYP2C19 allele affecting your clopidogrel response may not be on the standard panel

Your cardiologist needs an actionable diplotype before prescribing, not a variant list

Others in Pharmacogenomics

One test. A lifetime of answers.